Article
Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.
PharmacoEconomics - 1 Jan 2006
Priest Virginia L, Begg Evan J, Gardiner Sharon J, Frampton Christopher M A, Gearry Richard B, Barclay Murray L, Clark David W J, Hansen Paul
Abstract excerpt
OBJECTIVES: To compare the cost effectiveness of azathioprine (AZA), methotrexate (MTX) and no immunosuppression for maintaining remission of moderate to severe inflammatory bowel disease (IBD) in New Zealand Caucasians, and to determine whether prospective testing for poor metabolisers of AZA by genotype or phenotype is cost effective. METHODS: Pharmacoeconomic models were developed to compare treatment costs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.